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Reply to letter by Nardelli and Schell commenting on
the pathogenesis of Lyme arthritis
To the Editor:
In a recent letter to the editor (1) about our article on
the pathogenesis of Lyme arthritis and the role that cytokines
play in the process (2), Drs. Nardelli and Schell make impor-
tant points that are largely consistent with our own findings.
In particular, the authors stress that Th1 cells, producing high
levels of interferon- [IFN], are not solely responsible for the
induction of Lyme arthritis (3,4), since experimental Lyme
arthritis can occur and propagate even in IFN-deficient mice
(5,6). The possible involvement of interleukin-17 (IL-17) in
the genesis of Lyme arthritis is suggested by the observations
that IL-17 inhibition prevents the development of arthritis in
vaccinated mice challenged with Borrelia burgdorferi (7), and
that T cell priming with peptides in the presence of B burg-
dorferi induces IL-17 production in Th cells (8). In our study,
we demonstrated that T cells from the synovial fluid of pa-
tients with Lyme arthritis produce IL-17 in response to the
neutrophil-activating protein A (NapA) of B burgdorferi (2).
Second, Nardelli and Schell state their support for
the hypothesis that Th17-associated cytokines, such as IL-23,
transforming growth factor  (TGF), and IL-6, are also in-
volved in the Borrelia-mediated arthritic processes in mice (9).
We are strongly in favor of this hypothesis. Our findings in
human subjects revealed that B burgdorferi NapA is able to
induce the expression of IL-6, IL-1, and TGF in monocytes,
and IL-23 in neutrophils and monocytes (2).
Third, the authors suggest that Treg cells might also
influence the development of Lyme arthritis, since neutraliza-
tion of IL-17 in Borrelia-vaccinated and -infected mice is
associated with both an increased number of CD4CD25 T
cells in the local lymph nodes and the prevention of severe
destructive arthritis (10). Furthermore, it has been demon-
strated that TGF activates Treg cell responses regardless of
the combination of TGF, IL-23, and IL-6 that is driving Th17
responses (11). Thus, on the basis of the results obtained so far
in humans (2) and in mice (7), it can be speculated that the
relative amount of the different cytokines (TGF, or TGF
plus IL-23, IL-6, and IL-1) present in the local synovium
might dictate the progression of the disease toward more
severe destructive arthritis.
Overall, considering the results obtained in humans (2)
and in studies of Borrelia-vaccinated and -challenged mice by
Drs. Nardelli and Schell (7) and others, we conclude that in
B burgdorferi infection, a synovial Th17 response (Figure 1)
plays an important role in the genesis of Lyme arthritis, and
that further exploration of the mechanisms regulating the Th17
pathway may prove helpful in the design of novel tools for the
prevention and treatment of the disease.
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Figure 1. The synovial Th17 response in Borrelia burgdorferi infection.
NapA  neutrophil-activating protein A; IL-23  interleukin-23;
TGF  transforming growth factor .
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